ACAD - アカディア・ファ―マシュ―ティカルズ (ACADIA Pharmaceuticals Inc.)

ACADのニュース

   2020 Depression Pipeline Landscape Insights: H1  2020/04/27 16:45:00 Benzinga Feeds
DUBLIN , April 27, 2020 /PRNewswire/ -- The "Depression - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This pipeline guide provides an overview of the Depression (Central Nervous System) pipeline landscape. It provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. It also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 16, 36, 42, 4, 86, 22 and 5 respectively.
   ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020  2020/04/15 20:05:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Thursday, May 7, 2020, after the close of the U.S. financial markets. ACADIA’s management team will also host a conference call and webcast on Thursday, May 7, 2020, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-
   Goldman likes GW Pharma in premarket analyst action  2020/03/06 12:22:23 Seeking Alpha
ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with Buy rating and $69 (55% upside) price target at Citigroup. Alector (NASDAQ:ALEC) initiated with Buy rat
   ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome  2020/03/03 22:50:00 Business Wire
SAN DIEGO & MELBOURNE, Australia--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder. Upon FDA approval of a product with RPD designation, the sponsor may be eligible to receive a Priority Review Voucher, which can be used to obtain FDA r
   ACADIA Pharma EPS beats by $0.03, beats on revenue  2020/02/26 21:13:40 Seeking Alpha
ACADIA Pharma (NASDAQ:ACAD): Q4 GAAP EPS of -$0.34 beats by $0.03. Revenue of $98.33M (+65.0% Y/Y) beats by $1.64M. Press Release
   2020 Depression Pipeline Landscape Insights: H1  2020/04/27 16:45:00 Benzinga Feeds
DUBLIN , April 27, 2020 /PRNewswire/ -- The "Depression - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This pipeline guide provides an overview of the Depression (Central Nervous System) pipeline landscape. It provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. It also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 16, 36, 42, 4, 86, 22 and 5 respectively.
   ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020  2020/04/15 20:05:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Thursday, May 7, 2020, after the close of the U.S. financial markets. ACADIA’s management team will also host a conference call and webcast on Thursday, May 7, 2020, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-
   Goldman likes GW Pharma in premarket analyst action  2020/03/06 12:22:23 Seeking Alpha
ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with Buy rating and $69 (55% upside) price target at Citigroup. Alector (NASDAQ:ALEC) initiated with Buy rat
   ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome  2020/03/03 22:50:00 Business Wire
SAN DIEGO & MELBOURNE, Australia--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder. Upon FDA approval of a product with RPD designation, the sponsor may be eligible to receive a Priority Review Voucher, which can be used to obtain FDA r
   ACADIA Pharma EPS beats by $0.03, beats on revenue  2020/02/26 21:13:40 Seeking Alpha
ACADIA Pharma (NASDAQ:ACAD): Q4 GAAP EPS of -$0.34 beats by $0.03. Revenue of $98.33M (+65.0% Y/Y) beats by $1.64M. Press Release
   ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020  2020/01/07 14:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2020, at 10:00 a.m. Pacific Time, followed by a question and answer breakout session. A live webcast of ACADIA’s presentation
   Has ACADIA Pharmaceuticals (ACAD) Outpaced Other Medical Stocks This Year?  2019/12/23 16:30:09 Zacks Investment Research
Is (ACAD) Outperforming Other Medical Stocks This Year?
   ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer  2019/12/18 21:05:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Stephanie Fagan has been appointed to the newly created position of Senior Vice President, Corporate Affairs and Chief Communications Officer. Ms. Fagan will be responsible for all corporate communications and serve as a member of the company’s Executive Management Committee. She will report to Elena Ridloff, CFA, Executive Vice President, Chief Financial Officer of ACADIA. “Stephanie brings extensive ex
   The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend  2019/12/06 12:39:38 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented positive Phase 3 data for pimavanserin in dementia-related psychosis) Allergan plc (NYSE: AGN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Applied Therapeutics Inc (NASDAQ: APLT ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH )( reported positive readout for a pivotal trial in volcosporin for lupus nephritis) Bristol-Myers Squibb Co (NYSE: BMY ) Cassava Sciences Inc (NASDAQ: SAVA ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Incyte Corporation (NASDAQ: INCY ) Merck & Co., Inc. (NYSE: MRK ) Morphosys Ag (NASDAQ: MOR ) NuVasive, Inc. (NASDAQ: NUVA ) Oyster Point Pharma Inc (NASDAQ: OYST ) PTC Therapeutics, Inc.
   Biotech Stocks Are Making Wild Moves Amid a Deluge of Trial Data  2019/12/05 15:08:00 Barron's
Drug-trial news sent Aurinia and Acadia Pharmaceuticals soaring this morning and Sage Pharmaceuticals tumbling in early trading.

calendar